Idenix Pharmaceuticals Inc (NASDAQ:IDIX)
During the Trading Day
| 4.31 |  +0.12 / +2.86% |
Data as of 3:59pm ET | Day’s Change |
During After-Hours Switch to standard view »
| 4.31 |  0.00 / 0.00% |
Volume: 1.0K |
Latest IDIX News | Press Releases
No recent news for Idenix Pharmaceuticals Inc.
Today’s Trading
| Previous close | 4.19 |
| Today’s open | 4.20 |
| Day’s range | 4.12 - 4.47 |
| Volume | 1,006,798 |
| Average volume (3 months) | 889,712 |
| Market cap | $561.3M |
| Dividend yield | -- |
Data as of 3:59pm ET, 05/24/2013
Growth & Valuation
| Earnings growth (last year) | +52.63% |
| Earnings growth (this year) | -225.66% |
| Earnings growth (next 5 years) | -97.81% |
| Revenue growth (last year) | +902.20% |
| P/E ratio | NM |
| Price/Sales | 8.27 |
| Price/Book | 2.56 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| KERXKeryx Biopharmaceuti... | 0.00 | 0.00% |
| SGYPSynergy Pharmaceutic... | +0.05 | +1.08% |
| SGMOSangamo BioSciences ... | +0.05 | +0.63% |
| QLTIQLT Inc | -0.07 | -0.89% |
Data as of 4:00pm ET, 05/24/2013
Financials
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | -$0.22 |
| Annual revenue (last year) | $69.7M |
| Annual profit (last year) | -$32.4M |
| Net profit margin | -46.51% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Ronald C. Renaud, Jr., MBA |
Chief Financial Officer, Treasurer & Senior VP Daniella Beckman, CPA |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
